I am a healthcare professional

Notice


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.


Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.


By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


Cookies


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.


You can find out more about cookies by browsing our Privacy Policy.

 

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.

Leave site
Roche and Genentech at

CTAD 2026

We will be contributing to topics related to
-
07:00 PM
Duration 60mins Boston, USA
Rationale and design of TARBELA-AD: A Phase II, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of the NLRP3 inhibitor RG6434 in early symptomatic Alzheimer's disease
Loes Rutten-Jacobs, Venissa Machado, Paul Edison, Catherine Mummery, Alessandro Padovani, Malú Gámez Tansey, Silke Simon,Celine Adessi, Nikhat Parkar, Nima Shariati, Bastian Zinnhardt, Gabriel Schnetzler, Geoffrey A. Kerchner, Luka Kulic, Gennaro Pagano
Duration 60mins Boston, USA
Sex Matters in Alzheimer’s Disease: Gaps and Recommendations for Clinical Trials
Gillian Coughlan, Jill M. Goldstein, Roberta Diaz Brinton, Kristine Yaffe, Emily G. Jacobs, Roberta Marongiu, Kathryn Godburn Schubert, Heather Snyder, Jessica Z. K. Caldwell, Anna Chodos, Michelle Mielke, Lindsay R. Chura, Diana Slowiejko, Rachel Buckley
08:25 PM
Duration 20mins Boston, USA
A glimpse of the future: How diagnostics, therapies, trials, and concepts of prevention must evolve
Geoffrey A. Kerchner
09:50 PM
Duration 40mins Boston, USA
Advanced imaging results from the Brainshuttle™ AD study with trontinemab in Alzheimer’s disease
Gregory Klein, Gil D. Rabinovici, Henrik Zetterberg, Matteo Tonietto, Erica Silvestri, Anton Belousov, Fabien Alcaraz, Carsten Hofmann, João A. Abrantes, Orwa Albitar, Denise Sickert, Jakub Wojtowicz, Moreen Gabriel, Silke Ahlers, Paul Delmar, Janice Smith, Hanno Svoboda, Luka Kulic
Duration 40mins Boston, USA
Trontinemab in Alzheimer’s Disease- Novel Pharmacodynamic insights from the ongoing phase IB/IIA Brainshuttle™ AD study
Luka Kulic, Carsten Hofmann, João A. Abrantes, Fabien Alcaraz1 Gregory Klein, Denise Sickert, Jakub Wojtowicz, Moreen Gabriel, Silke Ahlers, Paul Delmar, Janice Smith, Hanno Svoboda
07:35 PM
Duration 40mins Boston, USA
The NLRP3 inflammasome as a therapeutic target in Alzheimer’s disease: biomarker, preclinical evidence and Phase I healthy participants’ safety data of the oral inhibitor RG6434
Gennaro Pagano
02:55 PM
Duration 30mins Boston, USA
PrevenTRON: Evaluating the effect of trontinemab in cognitively unimpaired individuals with biomarkers of Alzheimer’s disease at high risk of clinical decline
Reisa Sperling, Catherine Mummery, Jeffrey L. Cummings, Gil Rabinovici, Stephen Salloway, Henrik Zetterberg, Juan Fortea, Frank G. Boess, Christopher Lane, Marion Monchalin, Paul Delmar, Luka Kulic, Hanno Svoboda, Geoffrey A. Kerchner, Janice Smith
12:15 PM
Duration 60mins Boston, USA
REACHED: Participant characteristics from a pilot pre-screening study designed to diversify clinical trial recruitment in understudied populations in Alzheimer’s disease
Alexandria Wise-Brown, Alison Buick, Frank Boess, Frank Perilli, Ira Goodman, Janice Smith, Karra Harrington, Kelly Coultes, Nicklas Linz, Nicola Antonio Maiorano, Ruth Croney
Duration 60mins Boston, USA
Clinical and Operational Determinants of Amyloid-Targeting Therapy Initiation in Early Alzheimer's Disease: A Discrete Choice Experiment
Elena García-Arcelay, Juan Fortea, Alberto Villarejo, Raquel Sánchez-Valle, Neus Canal, Mónica Sarmiento, Jorge Mauriño, Guillermo García-Ribas, Gustavo Saposnik
Coming soon